Review Article | Published:

Cell therapy trials for heart regeneration — lessons learned and future directions

Nature Reviews Cardiologyvolume 15pages659671 (2018) | Download Citation


The effects of cell therapy on heart regeneration in patients with chronic cardiomyopathy have been assessed in several clinical trials. These trials can be categorized as those using noncardiac stem cells, including mesenchymal stem cells, and those using cardiac-committed cells, including KIT+ cardiac stem cells, cardiosphere-derived cells, and cardiovascular progenitor cells derived from embryonic stem cells. Although the safety of cell therapies has been consistently reported, their efficacy remains more elusive. Nevertheless, several lessons have been learned that provide useful clues for future studies. This Review summarizes the main outcomes of these studies and draws some perspectives for future cell-based regenerative trials, which are largely based on the primary therapeutic target: remuscularization of chronic myocardial scars by exogenous cells or predominant use of these cells to activate host-associated repair pathways though paracrine signalling. In the first case, the study design should entail delivery of large numbers of cardiac-committed cells, supply of supportive noncardiac cells, and promotion of cell survival and appropriate coupling with endogenous cardiomyocytes. If the primary objective is to harness endogenous repair pathways, then the flexibility of cell type is greater. As the premise is that the transplanted cells need to engraft only transiently, the priority is to optimize their early retention and possibly to switch towards the sole administration of their secretome.

Key points

  • Clinical trials of cell therapy for cardiac repair and regeneration in chronic heart failure conducted so far have yielded neutral or at most marginally positive outcomes.

  • Among adult tissue sources, mesenchymal stem cells (mostly from the bone marrow or adipose tissue) seem to hold great promise owing to the high secretory profile of these cells.

  • Although robust comparative studies are lacking, cardiac-committed cells, particularly those derived from pluripotent stem cells, could provide superior benefits compared with cells of a noncardiac lineage.

  • The main driver of future clinical trial design should be the primary therapeutic target (remuscularization or enhancement of intrinsic repair); statistical models might need to be re-evaluated to streamline the implementation of these studies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Bergmann, O. et al. Evidence for cardiomyocyte renewal in humans. Science 324, 98–102 (2009).

  2. 2.

    Psaltis, J. P., Schwarz, N., Toledo-Flores, D. & Nicholls, J. S. Cellular therapy for heart failure. Curr. Cardiol. Rev. 12, 195–215 (2016).

  3. 3.

    Mocini, D. et al. Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting. Am. Heart J. 151, 192–197 (2006).

  4. 4.

    Menasché, P. et al. Myoblast transplantation for heart failure. Lancet 357, 279–280 (2001).

  5. 5.

    Menasché, P. et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117, 1189–1200 (2008).

  6. 6.

    Miyagawa, S. et al. Phase I clinical trial of autologous stem cell–sheet transplantation therapy for treating cardiomyopathy. J. Am. Heart Assoc. 6, e003918 (2017).

  7. 7.

    Orlic, D. et al. Bone marrow cells regenerate infarcted myocardium. Nature 410, 701–705 (2001).

  8. 8.

    Hendrikx, M. et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation 114, I101–107 (2006).

  9. 9.

    Ang, K.-L. et al. Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nat. Clin. Pract. Cardiovasc. Med. 5, 663–670 (2008).

  10. 10.

    Pätilä, T. et al. Autologous bone marrow mononuclear cell transplantation in ischemic heart failure: a prospective, controlled, randomized, double-blind study of cell transplantation combined with coronary bypass. J. Heart Lung Transplant. 33, 567–574 (2014).

  11. 11.

    Perin, E. C. et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 307, 1717–1726 (2012).

  12. 12.

    Heldman, A. W. et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 311, 62–73 (2014).

  13. 13.

    Taylor, D. A. et al. Identification of bone marrow cell subpopulations associated with improved functional outcomes in patients with chronic left ventricular dysfunction: an embedded cohort evaluation of the FOCUS-CCTRN trial. Cell Transplant. 25, 1675–1687 (2016).

  14. 14.

    Heeschen, C. et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109, 1615–1622 (2004).

  15. 15.

    Contreras, A. et al. Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials. Bas. Res. Cardiol. 112, 3 (2017).

  16. 16.

    US National Library of Medicine. (2018).

  17. 17.

    Povsic, T. J. et al. The RENEW trial: efficacy and safety of intramyocardial autologous CD34( + ) cell administration in patients with refractory angina. JACC Cardiovasc. Interv. 9, 1576–1585 (2016).

  18. 18.

    Stamm, C. et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J. Thorac. Cardiovasc. Surg. 133, 717–725 (2007).

  19. 19.

    Nasseri, B. A. et al. Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial. Eur. Heart J. 35, 1263–1274 (2014).

  20. 20.

    Noiseux, N. et al. The IMPACT-CABG trial: a multicenter, randomized clinical trial of CD133+ stem cell therapy during coronary artery bypass grafting for ischemic cardiomyopathy. J. Thorac. Cardiovasc. Surg. 152, 1582–1588.e2 (2016).

  21. 21.

    Spees, J. L., Lee, R. H. & Gregory, C. A. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res. Ther. 7, 125 (2016).

  22. 22.

    Baron, F. & Storb, R. Mesenchymal stromal cells: a new tool against graft-versus-host disease? Biol. Blood Marrow Transplant. 18, 822–840 (2012).

  23. 23.

    Mathiasen, A. B. et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur. Heart J. 36, 1744–1753 (2015).

  24. 24.

    Bartunek, J. et al. Cardiopoietic stem cell therapy in heart failure. J. Am. Coll. Cardiol. 61, 2329–2338 (2013).

  25. 25.

    Bartunek, J. et al. Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur. Heart J. 38, 648–660 (2017).

  26. 26.

    Butler, J. et al. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II-A randomized trial. Circ. Res. 120, 332–340 (2017).

  27. 27.

    Patel, A. N. et al. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet 387, 2412–2421 (2016).

  28. 28.

    Povsic, T. J. & Zeiher, A. M. IxCELL-DCM: rejuvenation for cardiac regenerative therapy? Lancet 387, 2362–2363 (2016).

  29. 29.

    Perin, E. C. et al. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ. Res. 117, 576–584 (2015).

  30. 30.

    US National Library of Medicine. (2016).

  31. 31.

    Ascheim, D. D. et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation 129, 2287–2296 (2014).

  32. 32.

    Fisher, S. A., Doree, C., Mathur, A., Taggart, D. P. & Martin-Rendon, E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst. Rev. 12, CD007888 (2016).

  33. 33.

    Fisher, S., Doree, C., Taggart, D., Mathur, A. & Martin-Rendon, E. Cell therapy for heart disease: trial sequential analyses of two Cochrane reviews. Clin. Pharmacol. Ther. 100, 88–101 (2016).

  34. 34.

    Bianconi, V. et al. Endothelial and cardiac progenitor cells for cardiovascular repair: a controversial paradigm in cell therapy. Pharmacol. Ther. 181, 156–168 (2018).

  35. 35.

    Mishra, R. et al. Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation 123, 364–373 (2011).

  36. 36.

    Bolli, R. et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378, 1847–1857 (2011).

  37. 37.

    Smith, R. R. et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115, 896–908 (2007).

  38. 38.

    Malliaras, K. et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J. Am. Coll. Cardiol. 63, 110–122 (2014).

  39. 39.

    van Berlo, J. H. et al. c-Kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509, 337–341 (2014).

  40. 40.

    Koninckx, R. et al. Mesenchymal stem cells or cardiac progenitors for cardiac repair? A comparative study. Cell. Mol. Life Sci. CMLS 68, 2141–2156 (2011).

  41. 41.

    US National Library of Medicine. (2018).

  42. 42.

    Karantalis, V. et al. Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy. J. Am. Coll. Cardiol. 66, 1990–1999 (2015).

  43. 43.

    US National Library of Medicine. (2017).

  44. 44.

    US National Library of Medicine. (2017).

  45. 45.

    Capricor Therapeutics. Capricor Therapeutics provides update on ALLSTAR trial. PR Newswire (2017).

  46. 46.

    Lundy, S. D., Gantz, J. A., Pagan, C. M., Filice, D. & Laflamme, M. A. Pluripotent stem cell derived cardiomyocytes for cardiac repair. Curr. Treat. Options Cardiovasc. Med. 16, 319 (2014).

  47. 47.

    Bellamy, V. et al. Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold. J. Heart Lung Transplant. 34, 1198–1207 (2015).

  48. 48.

    Menasché, P. et al. Transplantation of human embryonic stem cell–derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 71, 429–438 (2018).

  49. 49.

    Wang, L. et al. Transplantation of Isl1+ cardiac progenitor cells in small intestinal submucosa improves infarcted heart function. Stem Cell Res. Ther. 8, 230 (2017).

  50. 50.

    Strauer, B. E. et al. Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction [German]. Dtsch. Med. Wochenschr. 126, 932–938 (2001).

  51. 51.

    Reinecke, H., Poppa, V. & Murry, C. E. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J. Mol. Cell. Cardiol. 34, 241–249 (2002).

  52. 52.

    Murry, C. E. et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428, 664–668 (2004).

  53. 53.

    Lang, C. I. et al. Cardiac cell therapies for the treatment of acute myocardial infarction: a meta-analysis from mouse studies. Cell. Physiol. Biochem. 42, 254–268 (2017).

  54. 54.

    Emmert, M. Y. et al. Safety and efficacy of cardiopoietic stem cells in the treatment of post-infarction left-ventricular dysfunction — from cardioprotection to functional repair in a translational pig infarction model. Biomaterials 122, 48–62 (2017).

  55. 55.

    Chimenti, I. et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ. Res. 106, 971–980 (2010).

  56. 56.

    Chong, J. J. H. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273–277 (2014).

  57. 57.

    Ye, J. et al. Treatment with hESC-derived myocardial precursors improves cardiac function after a myocardial infarction. PLoS ONE 10, e0131123 (2015).

  58. 58.

    Funakoshi, S. et al. Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes. Sci. Rep. 6, 19111 (2016).

  59. 59.

    Aonuma, T. et al. Apoptosis-resistant cardiac progenitor cells modified with apurinic/apyrimidinic endonuclease/redox factor 1 gene overexpression regulate cardiac repair after myocardial infarction: CPCs modified by APE1 regulate cardiac repair. Stem Cells Transl Med. 5, 1067–1078 (2016).

  60. 60.

    Zhu, P. et al. Melatonin protects ADSCs from ROS and enhances their therapeutic potency in a rat model of myocardial infarction. J. Cell. Mol. Med. 19, 2232–2243 (2015).

  61. 61.

    Kim, H. W., Haider, H. K., Jiang, S. & Ashraf, M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J. Biol. Chem. 284, 33161–33168 (2009).

  62. 62.

    Schwartz, S. D. et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 385, 509–516 (2015).

  63. 63.

    Iseoka, H. et al. Pivotal role of non-cardiomyocytes in electromechanical and therapeutic potential of induced pluripotent stem cell-derived engineered cardiac tissue. Tissue Eng. Part A 24, 287–300 (2017).

  64. 64.

    Chen, H.-S. V., Kim, C. & Mercola, M. Electrophysiological challenges of cell-based myocardial repair. Circulation 120, 2496–2508 (2009).

  65. 65.

    Garbern, J. C. & Lee, R. T. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 12, 689–698 (2013).

  66. 66.

    Li, T.-S. et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J. Am. Coll. Cardiol. 59, 942–953 (2012).

  67. 67.

    Weil, B. R., Suzuki, G., Leiker, M. M., Fallavollita, J. A. & Canty, J. M. Comparative efficacy of intracoronary allogeneic mesenchymal stem cells and cardiosphere-derived cells in swine with hibernating myocardium. Circ. Res. 117, 634–644 (2015).

  68. 68.

    Tano, N. et al. Allogeneic mesenchymal stromal cells transplanted onto the heart surface achieve therapeutic myocardial repair despite immunologic responses in rats. J. Am. Heart Assoc. 5, e002815 (2016).

  69. 69.

    Malliaras, K. et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 125, 100–112 (2012).

  70. 70.

    Hare, J. M. et al. Comparison of allogeneic versus autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308, 2369–2379 (2012).

  71. 71.

    Vrtovec, B. et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation 128, S42–49 (2013).

  72. 72.

    Hou, D. et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 112, I150–156 (2005).

  73. 73.

    van den Akker, F. et al. Intramyocardial stem cell injection: go(ne) with the flow. Eur. Heart J. 38, 184–186 (2017).

  74. 74.

    Behfar, A. et al. Optimized delivery system achieves enhanced endomyocardial stem cell retention. Circ. Cardiovasc. Interv. 6, 710–718 (2013).

  75. 75.

    Mitsutake, Y. et al. Improvement of local cell delivery using helix transendocardial delivery catheter in a porcine heart. Int. Heart. J. 58, 435–440 (2017).

  76. 76.

    Amer, M. H., Rose, F. R. A. J., White, L. J. & Shakesheff, K. M. A. Detailed assessment of varying ejection rate on delivery efficiency of mesenchymal stem cells using narrow-bore needles. Stem Cells Transl Med. 5, 366–378 (2016).

  77. 77.

    O’Neill, H. S. et al. Biomaterial-enhanced cell and drug delivery: lessons learned in the cardiac field and future perspectives. Adv. Mater. Deerfield Beach Fla. 28, 5648–5661 (2016).

  78. 78.

    Levit, R. D. et al. Cellular encapsulation enhances cardiac repair. J. Am. Heart Assoc. 2, e000367 (2013).

  79. 79.

    Parekkadan, B. & Milwid, J. M. Mesenchymal stem cells as therapeutics. Annu. Rev. Biomed. Eng. 12, 87–117 (2010).

  80. 80.

    Guo, Y. et al. Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction. Bas. Res. Cardiol. 112, 18 (2017).

  81. 81.

    US National Library of Medicine. (2017).

  82. 82.

    US National Library of Medicine. (2018).

  83. 83.

    Lee, R. H. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5, 54–63 (2009).

  84. 84.

    Tang, J. et al. Targeted repair of heart injury by stem cells fused with platelet nanovesicles. Nat. Biomed. Eng. 2, 17–26 (2018).

  85. 85.

    Penicka, M. et al. One-day kinetics of myocardial engraftment after intracoronary injection of bone marrow mononuclear cells in patients with acute and chronic myocardial infarction. Heart Br. Card. Soc. 93, 837–841 (2007).

  86. 86.

    Koczera, P. et al. PBCA-based polymeric microbubbles for molecular imaging and drug delivery. J. Control. Release 259, 128–135 (2017).

  87. 87.

    Kervadec, A. et al. Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure. J. Heart Lung Transplant. 35, 795–807 (2016).

  88. 88.

    Mohamed, T. M. A. et al. Chemical enhancement of in vitro and in vivo direct cardiac reprogramming. Circulation 135, 978–995 (2017).

  89. 89.

    Mann, D. L. et al. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. Eur. J. Heart Fail. 18, 314–325 (2016).

  90. 90.

    US National Library of Medicine. (2017).

  91. 91.

    Fischer-Rasokat, U. et al. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ. Heart Fail. 2, 417–423 (2009).

  92. 92.

    Bittner, V. et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA 270, 1702–1707 (1993).

  93. 93.

    Onisko, A., Druzdzel, M. J. & Austin, R. M. How to interpret the results of medical time series data analysis: classical statistical approaches versus dynamic Bayesian network modeling. J. Pathol. Inform. 7, 50 (2016).

  94. 94.

    Fernández-Avilés, F. et al. Global position paper on cardiovascular regenerative medicine. Eur. Heart J. 38, 2532–2546 (2017).

  95. 95.

    Wang, H. et al. A physiologically based kinetic model for elucidating the in vivo distribution of administered mesenchymal stem cells. Sci. Rep. 6 (2016).

  96. 96.

    Elman, J. S. et al. Pharmacokinetics of natural and engineered secreted factors delivered by mesenchymal stromal cells. PLoS ONE 9, e89882 (2014).

  97. 97.

    Brooks, A. et al. Concise Review: Quantitative detection and modeling the in vivo kinetics of therapeutic mesenchymal stem/stromal cells: detection and modeling kinetics of stem cells. Stem Cells Transl Med. 7, 78–86 (2018).

  98. 98.

    Oransky, I. Harvard-Brigham heart researcher under investigation earns Lancet Expression of Concern. Retraction Watch (2014).

Download references

Reviewer information

Nature Reviews Cardiology thanks F. Fernández-Avilés, A. Behfar, and the other, anonymous reviewer(s) for their contribution to the peer review of this work.

Author information


  1. Department of Cardiovascular Surgery, Université Paris Descartes, Sorbonne Paris Cité, INSERM U-970, Hôpital Européen Georges Pompidou, Paris, France

    • Philippe Menasché


  1. Search for Philippe Menasché in:

Competing interests

The author declares no competing interests.

Corresponding author

Correspondence to Philippe Menasché.



The unique capacity of stem cells to self-renew and to differentiate into multiple lineages.


Derived from the same individual.


Technology in which the blood is passed through a device that separates one particular blood constituent and returns the remainder to the bloodstream.

Cardiosphere-derived cells

Cells outgrowing from in vitro cultured tissue retrieved from the right ventricle by a transvenous endoventricular biopsy.

Embryonic stem cells

(ESCs). Cells taken from 4–6 day embryos, a stage at which the cells are still pluripotent and thus able to give rise to all cell types in response to the appropriate cues.

Induced pluripotent stem cells

(iPSCs). Adult cells that have been reprogrammed to an embryonic-like pluripotent state.


Derived from genetically different individuals of the same species.


Derived from genetically identical individuals and thus equivalent to autologous.

About this article

Publication history


Issue Date


Further reading